about
Combined fiber modifications both to target α(v)β(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5.Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest.Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy.Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapyIonic immune suppression within the tumour microenvironment limits T cell effector function.Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy.PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.The expanding role of immunotherapy.Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients.Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.Immunogenicity of somatic mutations in human gastrointestinal cancers.GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution.Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh TumorVerapamil enhances the antitumoral efficacy of oncolytic adenoviruses.Positive selection of gene-modified cells increases the efficacy of pancreatic cancer suicide gene therapy.A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses.Urokinase-type plasminogen activator receptor transcriptionally controlled adenoviruses eradicate pancreatic tumors and liver metastasis in mouse modelsBioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potency.Syncytia formation affects the yield and cytotoxicity of an adenovirus expressing a fusogenic glycoprotein at a late stage of replication.Deletion of VAI and VAII RNA genes in the design of oncolytic adenoviruses.Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting.Adenovirus i-leader truncation bioselected against cancer-associated fibroblasts to overcome tumor stromal barriers.Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens.Selection of circulating PD-1+ lymphocytes from cancer patients enriches for tumor-reactive and mutation-specific lymphocytes.Durable complete response in a patient with metastatic melanoma following adoptive transfer of autologous T cells recognizing 10 mutated tumor antigens.Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma.Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapyCancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancerRecognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytesIntratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T CellsDeterminants for Neoantigen Identification
P50
Q33401839-DB774EAA-1C1E-406A-9EFA-D9940E30D238Q34892977-8C1F63FD-7732-4280-9219-EE491503F052Q35257907-0E969835-56B1-412F-AA1E-25FD2E419D50Q36154471-68ADEEEF-F37B-4EB4-9DB3-821B9210FEDCQ36430680-00DFFBAF-494A-4CB6-9D14-EF274AC52B6FQ36637039-1B1F3EAB-0709-4AF3-B041-5D46071A643BQ37107516-E90BA3FF-9536-46EA-91F0-DF29E111E8E2Q37548587-167C0B09-369D-4221-80DB-8AA3BDD6909CQ37590119-AC444BF2-F5EE-4B65-AAD7-0595774EC0BFQ37726682-6F246D75-9007-4CAC-9515-3B91871A7CFAQ38754012-2D8CA7A9-A77C-486E-8C6E-0877C08A3228Q38792012-853C87C7-D975-4CBB-A8EA-E739DCC89DC0Q38797183-7B899655-FA68-46A8-A3F7-C9774E335995Q38823554-1F2BADB0-9200-4665-BDEE-743DB68BF782Q39437927-B45F5625-FD6E-42B6-A703-E693FBBC8DCBQ39647119-7A374FA0-6911-49FB-8F93-EA533D45411AQ39735941-8B43FBEF-89E9-4200-8ED3-86E134946F63Q39779454-F612B750-0F27-40FC-8994-1FEB49663C0EQ39807606-6CD29471-4689-4EC6-8C87-85577939BD87Q39844612-015A0A1E-E6FC-4D1A-9D97-82579DD9CEA2Q39923110-E4777B61-F22C-49AA-96F7-5FCC26C8E0B3Q39977445-9877DEDE-C330-4DDF-B6AA-6568885B9289Q40232066-21648836-F647-4F36-AEE3-88799D6B672BQ40246209-2180117D-48FA-40B7-AB46-E2752AF12F65Q40310120-0129C2BD-9397-489C-A02A-3D234658E932Q41958978-BAD6E2A4-C349-444C-8F58-710597310990Q45785742-4FEF962F-FBF5-4BA5-84A1-563AC19588EBQ45893979-050BCA91-BB59-4D28-8B84-8D7F2BA2FF14Q55056515-7EEEDED7-0DCC-4BAE-9324-223581CF5FA7Q57029270-0A7D3BEB-3E68-4F87-956E-2E55026B265FQ57152489-3CE314C2-F915-4729-8DAF-8A175979E7E2Q90688967-660C9A52-ECB5-45EA-BC63-B4B274008587Q91421884-F14620BF-1490-4E3A-ACD4-6A3FD5F366DDQ91782530-6D5CB992-5E71-473B-967C-1D7E9F3F5EF7
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alena Gros
@ast
Alena Gros
@en
Alena Gros
@es
Alena Gros
@nl
type
label
Alena Gros
@ast
Alena Gros
@en
Alena Gros
@es
Alena Gros
@nl
prefLabel
Alena Gros
@ast
Alena Gros
@en
Alena Gros
@es
Alena Gros
@nl
P106
P1153
15052882700
P21
P31
P496
0000-0002-1207-1880